期刊文献+

动脉内溶栓后低分子肝素治疗急性脑梗死11例 被引量:2

Urgent intra-arterial thrombolysis and low molecular weight heparin therapy for acute cerebral infarction: a report of 11 cases
下载PDF
导出
摘要 目的观察急诊动脉内溶栓加低分子肝素治疗急性脑梗死的疗效及预后。方法对11例治疗时间窗在6h内的急性脑梗死患者行动脉内溶栓治疗。术前及术后24h均行神经功能评价(美国国立卫生研究院卒中量表,NIHSS)。术后根据急性心肌梗死溶栓标准灌注分级(TIMI)评价血管再通程度。溶栓后20d,皮下注射低分子肝素钙5000U。20d后,根据改良的Rank分数法(MRS)评价独立生活能力。结果溶栓前,患者NIHSS评分平均为17±8,术后24h为10±9,溶栓前后比较差异有显著意义(P<0.05)。24h神经功能评价,7例改善,4例无改善,差异有显著意义(P<0.05)。溶栓后7例患者完全再通,1例部分再通,3例未再通。MRS评分,8例患者疗效良好,3例疗效差,其中1例死亡。结论急诊动脉内溶栓是安全、可行的,溶栓后24h神经功能检查改善程度与20d后临床疗效密切相关,用低分子肝素作为溶栓后续治疗安全有效。 Objective To study the effect a nd complications of intra-arterial thrombolysis (IAT) and low-molecular-weight heparin in the treatment of acute ischemic stroke. To analyze the predictive fac tors related to the outcome. Methods 11 patients of acute isc hemic stroke were treated by IAT using urokinase(UK) within 6 h of onset in our hospital. Mechanical thrombolysis was attempted before UK was infused.Angiograp hic recanalization was classified according to Thrombolysis In Myocardial Infarc tion(TIMI).Clinical outcome was classified as good for Modified Rankin Scale (MR S)scores of 0 to 3 and poor for MRS scores of 4 to 6. Results There were 6 patients TIMI 0-1 and 5 patients TIMI 2 before thrombolysis was performed. The rates of complete/partial recanalization just after infusion wer e 8 cases and minimal or no recanalization were 3 cases.8 of the 11 patients had good outcome and 3 had poor outcome. Conclusion IAT is feasi ble and safe in patients suffered from acute stroke. Improvement by 4 or more po ints on NIHSSS within 24 hours was significantly associated with good outcome. W hether adopting the mechanical disruption method was determined by the time of stroke onset and occlusion site. low-molecular-weight heparin in the thrombol ysis treatment of acute ischemic stroke was safe and feasible.
出处 《中国脑血管病杂志》 CAS 2005年第4期156-159,共4页 Chinese Journal of Cerebrovascular Diseases
  • 相关文献

参考文献11

  • 1[1]全军脑血管病流调协作组.我国脑血管病流行病学研究.北京:人民军医出版社,1993.217-231.
  • 2王忠诚,程学铭,李世绰,等.北京市西长安街地区居民神经系疾病的流行病学调查[J].中华神经精神科疾病杂志,1981,(17):72-75.
  • 3[3]Quality Standards Subcommittee of the American Academy of Neurology. Practice advisory: thrombolytic therapy for acute ischemic stroke - summary statement, report of the quality standards subcommittee of the American Academy of Neurology. Neurology, 1996, 47: 835-839.
  • 4[4]Wolpert SM, Bruckmann H, Greenlee R, et al. Neuroradiologic evaluation of patients with acute stroke treated with recombinant tissue plasminogen activator. The ft-PA acute stroke study group. AJNR, 1993, 14, 3-13.
  • 5[5]Theron J, Courtheoux P, Casasco A, et al. Local intra-arterial fibrinolysis in the carotid territory. AJNR, 1989, 10: 753-765.
  • 6[6]Theron J, Coskun O, Huet H, et al. Local intra-arterial thrombolysis in the carotid territory. Intervent Neuroradiol,1996, 2: 111-126.
  • 7[7]Berlis A, Lutsep H, Barnwell S, et al. Mechanical thrombolysis in acute ischemic stroke with endovascular photoacoustic recanalization , Stroke, 2004, 35: 1112.
  • 8[8]Wallentina L, Bergstrandb L, Dellborgc M, et al. Low molecular weight heparin (dalteparin) compared to unfractionated heparin as an adjunct to rt-PA (alteplase) for improvement of coronary artery patency in acute myocardial infarction-the ASSENT Plus study. Euro Heart J, 2003, 24: 897-908.
  • 9[9]The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med, 1995, 333:1581-1587.
  • 10[10]del Zoppo GJ, Higshida RT, Furlan AJ, et al. PROACT: a phase II randomized trial of recombinant pro-urokinade by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators. Prolyse in acute cerebral thromboembolism. Stroke, 1998, 29: 4-11.

同被引文献12

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部